Recent Updates
Recently added Catalysts
CDNA Positive Sentiment

CareDx Announces Third KOAR Analysis Published in Transplantation

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CareDx announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry in the journal Transplantation. This third manuscript explores the relationship between early post-transplant AlloSure kidney donor-derived cell-free DNA levels and transplant outcomes. The findings aim to enhance understanding of kidney transplant success.

Market Sentiment Analysis

POSITIVE FACTORS

  • Publication of significant findings in a reputable journal.
  • Insights into early post-transplant outcomes.
  • Contribution to the Kidney Allograft Outcomes AlloSure Registry.

Full Press Release Details

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multicenter study, in the journal Transplantation. The third manuscript from KOAR investigated the correlation between early post-transplant AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) levels and thr

Frequently Asked Questions

What is the KOAR study?

The KOAR study is a multicenter research initiative focused on kidney transplant outcomes.

Where was the KOAR analysis published?

The analysis was published in the journal Transplantation.

What does dd-cfDNA stand for?

dd-cfDNA stands for donor-derived cell-free DNA.

What does the new analysis investigate?

It investigates the correlation between early post-transplant dd-cfDNA levels and outcomes.

ShareAdd on Google
Tags: CDNA CareDx KOAR transplantation dd-cfDNA kidney transplant
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$250M liquidity · $0M/mo burn
Low dilution risk